Suven patents neurological molecules in India, HK and US
16 November 2017
Suven Life Sciences has secured four product patents, including two from India and one each from Hong Kong and the United States for its new chemical entities, (NCEs) which could be used for the treatment of disorders associated with Neurodegenerative diseases.
The granted claims of the patents include the class of selective H3 and 5-HT6 compounds and these patents - (1204620-HK), (287865 and 289092-India) and (9802896-USA) - are valid through 2032, 2030 and 2034, respectively, Suven said in a release.
Suven said the compounds are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
''We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally'' Venkat Jasti, CEO of Suven, said.
Suven Life Science is a Hyderabad-based biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products. Suven has four clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and Phase 1 undergoing SUVN-911.
In addition to these clinical compounds the company has nine internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.